NasdaqGS:CRNXPharmaceuticals
Is It Too Late To Consider Crinetics Pharmaceuticals (CRNX) After Strong Multi‑Year Share Gains?
Investors may be wondering if Crinetics Pharmaceuticals at around US$55.41 per share is still offering fair value, or if the recent excitement has already been priced in.
The stock shows a flat 7 day return, while the 30 day return is 12.5%, year to date is 18.6%, and the 1 year return is 43.4%, with a very large 5 year gain of 282.9%. This performance may have changed how the market views its risk and potential.
Recent coverage has focused on Crinetics Pharmaceuticals as a growth oriented...